Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Biogen (NASDAQ:BIIB) traded ~8% higher in the premarket on Thursday after the company posted better-than-expected financials ...

Long-term treatment with lecanemab shows slowed progression of early Alzheimer’s disease, according to data presented at the ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

Eisai and Biogen announced FDA approval for LEQEMBI’s once every four weeks maintenance dosing for Alzheimer’s disease treatment.